Artificial intelligence for clinical oncology
Clinical oncology is experiencing rapid growth in data that are collected to enhance cancer
care. With recent advances in the field of artificial intelligence (AI), there is now a …
care. With recent advances in the field of artificial intelligence (AI), there is now a …
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …
[HTML][HTML] Improved outcomes with enzalutamide in biochemically recurrent prostate cancer
SJ Freedland, M de Almeida Luz… - … England Journal of …, 2023 - Mass Medical Soc
Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology
JL Mohler, ES Antonarakis, AJ Armstrong… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …
risk stratification and workup, treatment options for localized disease, and management of …
Molecular biomarkers in localized prostate cancer: ASCO guideline
PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …
cancer biomarkers geared toward patient selection for active surveillance, identification of …
Biomarkers for prostate cancer: prostate-specific antigen and beyond
MJ Duffy - Clinical Chemistry and Laboratory Medicine (CCLM), 2020 - degruyter.com
In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …
(PSA) have become available for men with prostate cancer. Although widely used in an ad …
The promising role of new molecular biomarkers in prostate cancer: From coding and non-coding genes to artificial intelligence approaches
AP Alarcón-Zendejas, A Scavuzzo… - Prostate cancer and …, 2022 - nature.com
Background Risk stratification or progression in prostate cancer is performed with the
support of clinical-pathological data such as the sum of the Gleason score and serum levels …
support of clinical-pathological data such as the sum of the Gleason score and serum levels …
Genomic markers in prostate cancer decision making
V Cucchiara, MR Cooperberg, M Dall'Era, DW Lin… - European urology, 2018 - Elsevier
Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …
Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial
Importance Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …